The efficacy of GLP‐1RA may be evaluated according to the expression level of Tipe1, and the simultaneous use of both would greatly improve the response of patients with T2D to GLP‐1RA therapy. The gene discussed is TIPE1; the disease is type 2 diabetes mellitus.